Presentation Focused on Positive Results from Recent Phase 2a Study PITTSBURGH, May 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has delivered a late-breaking presentation at the annual… Read More..

Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J., May 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it… Read More..

Deal Is Expected to Value Slacker at $160 Million Pre-Money Slacker Surges to Over 3 Million Members Adding Over 225K Since January 1, 2023* Byron Roth Expected to Remain on the Post-Merger Company's Board of Directors LOS ANGELES, CA , April 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - LiveOne (Nasdaq: LVO),… Read More..